LIMN

10-K - Liminatus Pharma, Inc. (0001971387) (Filer)

CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immune pathways and complement established immuno-oncology therapies. IBA101 is engineered to target the CD47 "don't-eat-me" signal, a mechanism that enables tumor cells to evade innate immune surveillance. By enhancing macrophage-mediated tumor clearance and antigen presentation, IBA101 is designed to work alongside PD-1/PD-L1 checkpoint inhibitors, which remain the backbone of treatment across multiple solid tumor indications. The planned Phase 1 study is designed as a s

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

SCHEDULE 13G - Liminatus Pharma, Inc. (0001971387) (Subject)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

424B4 - Liminatus Pharma, Inc. (0001971387) (Filer)

CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing of  its best-efforts public offering of 13,813,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded warrant) and accompanying warrants. The warrants will have an exercise price of $0.29 per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary

EFFECT - Liminatus Pharma, Inc. (0001971387) (Filer)

S-1 - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

10-Q - Liminatus Pharma, Inc. (0001971387) (Filer)

LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus's research and development of advanced immunotherapy assets. Subject to completion of diligence and the negotiation of definitive agreements, CTG intends to subscribe to newly issued shares of Liminatus, subject to compliance with Nasdaq listing rules and U.S. sec

10-Q - Liminatus Pharma, Inc. (0001971387) (Filer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

3 - Liminatus Pharma, Inc. (0001971387) (Issuer)

8-K - Liminatus Pharma, Inc. (0001971387) (Filer)

424B3 - Liminatus Pharma, Inc. (0001971387) (Filer)

EFFECT - Liminatus Pharma, Inc. (0001971387) (Filer)

LA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced plans for a strategic expansion into the cryptocurrency and blockchain sector. The company intends to establish a dedicated subsidiary, named "American BNB Strategy," to lead its digital asset investment and management initiatives. Through this planned vehicle, Liminatus aims to raise and deploy up to $500 million in phases, targeting strategic, long-term investments in BNB coin (Build and Build) the native token of the Binance ecosystem, the world's largest digital asset exc

LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment vehicle. This initiative marks a bold step toward positioning the Company at the forefront of capital innovation, as it evaluates options to diversify its long-term treasury strategy. The prospective subsidiary—which has not yet been formed and remains under active consideration—would operate independently of Limi

LA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced it has entered into an engagement agreement with Digital Offering LLC, a FINRA- and SEC-registered broker-dealer, to serve as its exclusive placement agent in connection with the company's evaluation of a potential strategic capital raise. This engagement supports Liminatus's previously disclosed review of a digital asset treasury strategy, as the company evaluates modern financial tools to strengthen its capital structure. The funding initiative may involve various exempt fi

3 - Liminatus Pharma, Inc. (0001971387) (Issuer)

LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework. This internal review is part of Liminatus's continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments—including blockchain-based assets—t